Trial Information

Summary: Phase II - Determining Mirapex ER efficacy, safety and tolerability in the treatment Parkinson's Disease

To determine the efficacy, safety and tolerability of Mirapex ER compared with placebo and Mirapex IR in patients with early onset of idiopathic Parkinson's Disease.

Patient Inclusion Criteria:

• Idiopathic Parkinson's Disease diagnosed within five years
• 30 years and older
• Anti-Parkinson treatment with anti-cholinergics, MAO inhibitors, and beta blockers allowed if there has been a stable dose for at least four weeks
• Modified Hoehn and Yahr stages 1-3

• Atypical Parkinsonian syndromes
• History of major psychological, neurological or neurodegenerative conditions
• History or recent diagnosis of malignant melanoma
• Treated with L-Dopa for more than eight weeks prior to starting in study
• Treated with a dopamine agonist within four weeks prior to starting in study

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:33:41 AM